<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642665</url>
  </required_header>
  <id_info>
    <org_study_id>S61372</org_study_id>
    <nct_id>NCT03642665</nct_id>
  </id_info>
  <brief_title>Natural Versus Artificial Cycle for Frozen-Thawed Embryo Transfer</brief_title>
  <acronym>NAFT</acronym>
  <official_title>Frozen-thawed Embryo Transfer in a Natural Versus Artificial Cycle: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GZA Ziekenhuizen Campus Sint-Augustinus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imelda Hospital, Bonheiden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates clinical pregnancy rates, obstetrical outcome parameters, costs and
      patient preferences in natural cycle versus artificial cycle frozen embryo transfers (FET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transfer of cryopreserved embryos can be performed in a natural cycle (NC-FET) or in an
      artificially prepared cycle (AC-FET). Both cycle regimens have their advantages and
      disadvantages. So far, most comparative studies have failed to identify the optimal protocol
      for FET. In this study patients undergoing FET will be randomized between an endometrial
      preparation by a natural cycle or by an artificial cycle (by oestradiol validate and
      micronized progesterone).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter prospective randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate with fetal heart beat</measure>
    <time_frame>9 weeks</time_frame>
    <description>Clinical pregnancy rate with fetal heart beat diagnosed by ultrasound no later than the gestational age of 9 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic pregnancy rate</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>41 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>tombo-embolic events, serious side-effects (car leaflet) which require cancellation of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle cancellation rate</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial pattern</measure>
    <time_frame>3 weeks</time_frame>
    <description>Sonographic aspect of the endometrium (triple-line, no triple-line)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of center visits to monitor FET cycle</measure>
    <time_frame>From date of randomization until the date of the embryo transfer or until cancellation (estimated period of time up to 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost analysis per treatment cycle</measure>
    <time_frame>From date of randomization until the date of the embryo transfer or until cancellation (estimated period of time up to 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effect of the different regimens on patients wellbeing/distress, Patient Reported Experience Measures (PREMS) from validated questionnaires will be used. Twenty-two questions from the Benyamini questionnaire will be used (Benyamini et al. 2005) and 10 questions from the subscales 'environment' (α=0.81) and 'tolerability' (α=0.75) of the FertilQol questionnaire (Pedro et al 2013). On the day of embryo transfer, the treating gynecologist will hand out the questionnaire to the patient. The patient will return the filled-in questionnaire on the day of the pregnancy test, before she knows the result of the pregnancy test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">554</enrollment>
  <condition>Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>Natural cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>no medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natural cycle</intervention_name>
    <description>no medication</description>
    <arm_group_label>Natural cycle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Valerate</intervention_name>
    <description>Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.</description>
    <arm_group_label>Artificial cycle</arm_group_label>
    <other_name>Artificial cycle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized progesterone</intervention_name>
    <description>Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.</description>
    <arm_group_label>Artificial cycle</arm_group_label>
    <other_name>Artificial cycle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing FET after a first, second or third fresh IVF/ICSI cycle

          -  Single embryo transfer (SET) or Double embryo transfer (DET)

          -  Female age between 18-45 year

          -  Women having a natural ovulatory cycle (24-35 days)

          -  Normal uterine cavity (fundal indentation at the cavity &lt;10mm)

          -  Written informed consent

        Exclusion Criteria:

          -  Use of donor gametes

          -  BMI &gt; or equal to 35 kg / m2

          -  Any contra-indication to estrogen or progesterone supplementation (e.g. history of
             thrombosis, prior or current hormone-sensitive malignancy…)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Myriam Welkenhuysen</last_name>
      <phone>+3216343544</phone>
      <email>myriam.welkenhuysen@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Brecht Geysenbergh, MD</last_name>
      <phone>+32496125137</phone>
      <email>brecht.geysenbergh@uzleuven.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

